Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3252159 | 0.98 | TACR1 (0.62) | TACR1SLC6A4KCNH2OPRM1 | |
| SCHEMBL27714635 | 0.90 | TACR1 (0.53) | TACR1SLC6A4KCNH2OPRM1 | |
| SCHEMBL19402984 | 0.87 | MAOA (0.54) | TACR1SLC6A4OPRM1 | |
| SCHEMBL14359682 | 0.83 | DPP4 (0.52) | TACR1SLC6A4 | |
| SCHEMBL10266904 | 0.83 | TACR1 (0.49) | TACR1SLC6A4KCNH2 | |
| SCHEMBL373790 | 0.83 | SLC6A4 (0.57) | TACR1SLC6A4KCNH2 | |
| SCHEMBL5357598 | 0.80 | TACR1 (0.54) | TACR1SLC6A4KCNH2 | |
| SCHEMBL3246807 | 0.79 | TACR1 (0.56) | TACR1SLC6A4KCNH2OPRM1 | |
| SCHEMBL4631291 | 0.79 | TACR1 (0.56) | TACR1SLC6A4KCNH2OPRM1 | |
| SCHEMBL1388435 | 0.78 | TACR1 (1.00) | TACR1SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-9873709-B2 | Triazolopyridine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | TACR1 2343/4885SLC6A4 378/4885KCNH2 1325/4885 |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | TACR1 1650/4885SLC6A4 2749/4885KCNH2 151/4885 |
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | TACR1 2662/4885SLC6A4 3188/4885KCNH2 1043/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | TACR1 1650/4885SLC6A4 2749/4885KCNH2 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.